Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

Conditions:   Breast Cancer Metastatic;   Breast Cancer Interventions:   Drug: Olaparib;   Drug: Vorinostat Sponsors:   Jenny C. Chang, MD;   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials